Our Science

World Leading Science

Genea Oxford's partnership with Australian fertility group Genea delivers direct access to a level of scientific expertise that is acknowledged across the world.

Genea is a fertility pioneer and has led the way in the treatment of infertility through IVF and other methods of assisted conception for 30 years. Research and improvements made by Genea virtually doubled IVF success rates in the mid-1990s and the group continues to develop world leading technology to treat a condition that affects as many as one in six New Zealand couples at some point in their relationship.

Genea's expertise in the science of fertility is a direct result of their commitment to funding research. The company has a long and proud history of investing in research and taking innovations from the lab into their clinics, meaning more of their patients (and patients from clinics around the world) realise their dream of creating a family.

Genea invests by far the most of any Australian clinic with at least 10 per cent of annual revenue on average going back into research - and substantially more over the past few years. That investment has led to many fertility breakthroughs over the years and that trend continues with some exciting new developments underway.

The combination of this scientific expertise with the local knowledge of Oxford Fertility means couples in Christchurch now have a viable choice when it comes to seeking help to achieve their dream of having a baby.

Read on below for some more insight into Genea's scientific heritage and fertility expertise.

Routine Day 5 embryo transfers

Genea was the first clinic in Australia to introduce routine Day 5 embryo transfers. Growing the embryos in the lab a little longer before transferring them to the female helps determine which embryos have the highest development potential and increases success rates. The time between Day 3 and Day 5 in an embryo’s life is critical because it’s when an embryo switches genetic control from the female’s genome to shared control between the female and male. This can be a point in the development of the embryo where problems occur and waiting to transfer embryos beyond it is far more successful. Genea has been giving patients world leading success rates with this advancement for years, and other Australian clinics have only recently followed their lead.

Single embryo transfer

Genea was also the first clinic in Australia to introduce routine single embryo transfer. While many clinics transfer more than one embryo to try to improve their chances of success, Genea's technology allows it to achieve higher success rates while transferring a single, carefully selected embryo.

Vitrification versus the old slow freeze method

Genea was the first clinic in Australia (it’s becoming a little repetitive isn’t it?) to develop and routinely replace the old slow freezing method for embryos, eggs and sperm with the more efficient and successful vitrification process. The technology, which is similar to snap freezing, has dramatically increased survival rates for thawed embryos. They’ve been using it routinely since February 2006 but some clinics still use the outdated slow freeze method.

Fertility Technologies

Genea don't just have access to the latest technologies - it pioneers them. Here are just some of the technologies Genea has played a major role in developing over the years.


Spending every day caring for your embryos, Genea’s embryologists are experts in what these precious potential babies need to survive and grow. So they developed a mini incubator that simulates the natural environment of human fallopian tubes by using low oxygen levels and introduce just the right amount of carbon dioxide to help embryos grow. The mini incubators or MINCs also maintain the optimal temperature to reduce stress on the embryo.

Genea Biomedx Culture Media - Gems®

The way eggs, sperm and embryos are nurtured and supported outside of the human body has been a key and consistent area of investment at Genea. For more than two decades, Genea scientists have been developing and refining culture media – the solutions which enable embryos to grow. Little surprise then that more than 600 clinics around the world nurture embryos using culture media developed by Genea. They have recently developed the next generation (Gems®) of this vital formula and have completed a rigorous clinical trial involving almost 700 Genea patients across all age groups and more than 15,000 eggs. The results are very positive with significantly better implantation rates and Gems is now exclusively available at Genea clinics.

Genea Biomedx Automated Vitrification - Gavi®

In 2015, one of Genea's sister companies, Genea Biomedx, will begin producing and selling an automated vitrification instrument - the first in the world. Genea’s scientists started with a simple question: “What if vitrification didn’t have to be a complex, time consuming task?” And in answer to that question, they conceived and designed Gavi®; - Genea Automated Vitrification Instrument - an instrument that automates the process of snap freezing embryos for use in later cycles. In the process, they’ve designed a tool which will standardise vitrification and, as a result, eliminate variation, and, we believe, ultimately improve outcomes for patients.

Quite simply, if you want to ensure that you benefit from the very latest assisted conception research and technology you could do no better than come to Genea Oxford.

For further information on how we can help you, contact us today or fill in the form below.

Make an enquiry

  • Please send me information and notice of events relating to fertility.
Genea has legal obligations to protect your personal information and to provide you with details about how we deal with this information. Please read our Privacy Policy and Collection Statement.